《Infectious Agents And Cancer》是一本以English為主的開放獲取國際優(yōu)秀期刊,中文名稱傳染性病原體和癌癥,本刊主要出版、報道醫(yī)學(xué)-IMMUNOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果,介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展,探討行業(yè)發(fā)展的思路和方法,以促進學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用,也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為3.1,最新CiteScore 指數(shù)為5.8。
本刊近期中國學(xué)者發(fā)表的論文主要有:
Brassicasterol inhibits hepatitis B virus-associated hepatocellular carcinoma development via suppression of AKT signaling pathway
Inhibitory effect and mechanism of Lactobacillus crispatus on cervical precancerous cells Ect1/E6E7 and screening of early warning factors
Author: Wan, B.; Wei, L. J.; Tan, T. M.; Qin, L.; Wang, H.
英文介紹
Infectious Agents And Cancer雜志英文介紹
Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer.
The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular:
? HPV and anogenital cancers, as well as head and neck cancers;
? EBV and Burkitt lymphoma;
? HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases;
? HHV8 and Kaposi sarcoma;
? HTLV and leukemia;
? Cancers in Low- and Middle-income countries.
The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries.
Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.